LNF 1901
Alternative Names: LNF-1901Latest Information Update: 02 Feb 2024
At a glance
- Originator Lunan Pharmaceutical Group
 - Class Antibodies; Antineoplastics; Immunotherapies; Monoclonal antibodies
 - Mechanism of Action Antibody-dependent cell cytotoxicity; CD40 antigen stimulants; T lymphocyte stimulants
 
- 
          
            
              Orphan Drug Status
              No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
 - New Molecular Entity Yes
 
Highest Development Phases
- Preclinical Cancer
 
Most Recent Events
- 26 Jan 2024 Shandong New Time Pharmaceutical plans a phase I trial for Cancer (Late-stage disease, Second-line therapy, Monotherapy) in February 2024 (IV) (NCT06226363)
 - 14 Apr 2023 Preclinical trials in Cancer in China (IV)
 - 14 Apr 2023 Pharmacodynamics and safety data from a preclinical studies in Cancer presented at the 114th Annual Meeting of the American Association for Cancer Research (AACR-2023)